Show 10 5 10 15 20 50 100 250 Sort by year (new to old) Actions Save this search Download search results Subscribe to news feed Your filters: cql: author="Salvati, Mark" or (type any "bookEditor journalEditor issueEditor" and editor="Salvati, M... Add to list Conference Paper C3 Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer Tanya Dorff, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey (UGent) , Nabil Adra, Mark Salvati, Shirley Poon, et al. (2020) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 8(Supplement: 3). p.A207-A208 Add to list Conference Paper C3 Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC). Ben Tran, Lisa Horvath, Matthew Rettig, Karim Fizazi, Martijn P. Lolkema, Tanya B. Dorff, Richard Greil, Jean-Pascal H. Machiels, Karen A. Autio, Sylvie Rottey (UGent) , et al. (2020) JOURNAL OF CLINICAL ONCOLOGY. 38(15).